Jonny Finlay is a serial biotech entrepreneur and co-founder of Ottimo Pharma, Centessa Pharmaceuticals and Granular Therapeutics; biologics drug discovery biotechs that are developing a series of therapeutics and technologies for oncology and inflammation indications. Jonny is a co-inventor of multiple clinical-phase antibodies including Afimkibart (RG6631, Roche, Ph3) and VM6 (Incyte, Ph1). He co-developed technologies used in the discovery of Marstacimab (Hympavzi), Ponsegromab and multiple other molecules now in clinical trials. He led influential research teams in Biologics Discovery and Development at Pfizer and carried out postdoctoral research in recombinant protein engineering at multiple institutes including CBER-FDA. 

Alex is the CEO of Diagonal Therapeutics, the company he founded in 2022, and an Entrepreneur-in-Residence at Atlas Venture. During his 20+ year career in biotechnology, he served as COO of Dragonfly Therapeutics, CDO of Morphic Therapeutic, VP of Therapeutics at Merrimack Pharmaceuticals, and Associate Director of Drug Discovery at Biogen. Alex is an author of over 100 patents and manuscripts and an Associate Editor of the mAbs, a journal dedicated to the art and science of antibody R&D. He has received an Advanced Certificate for Executives in Management, Innovation, and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University, an M.Sc. in Molecular Biophysics, and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology.

Dr Johan Fransson has more than 20 years of experience in the field of biologics discovery, engineering, and development. He has led teams in large pharma (Janssen R&D) and biotech (Northern Biologics, Prometheus Biosciences). He has brought several drug candidates from early target validation through discovery, optimization, lead identification, cell line development, IND-enabling studies, CMC, filing of INDs. In his role at Prometheus, he led the antibody and protein therapeutics group, which supported programs into clinical Ph1 and Ph2 PoC studies, with a specific focus on bioanalytical (PK, ADA, nAb) and target engagement / PD work. Prometheus was acquired by Merck Sharpe & Dohme (MSD) in 2023. Johan is currently an Executive Director at Merck Research Labs (MRL) San Diego, where he is leading the Biologics team with focus on developing differentiated therapeutics in Immunology and Inflammation.

Orla is currently CSO at Granular Therapeutics where she is driving the development of novel mast-selective therapies for chronic inflammatory disease. In addition, she is an advisor to Ottimo Pharma who have recently completed a $140M Series A to support clinical development of their highly differentiated PD1/VEGFR2 dual antagonist. Prior to this, Orla served as Senior Director at Pfizer where she led the European Biomedicine Design team. During this time, Orla was co-inventor of Afimkibart and led the early discovery and optimization of multiple clinical-stage molecules, including Ponsegromab. Throughout the course of her 20-year career in biotech, Orla has published and patented widely in the field of therapeutic antibody engineering. She holds a Ph.D. and a B.A.Mod in Biochemistry from Trinity College, Dublin.